Literature DB >> 15045637

A patient with hyper-IgD syndrome in Antalya, Turkey.

Erkan Coban1, Ender Terzioğlu.   

Abstract

Hyper-IgD syndrome is a periodic fever syndrome that presents with recurrent episodes of high fever accompanied by lymphadenopathy, abdominal distress, arthralgias or arthritis, headache and skin lesions. The diagnosis is based on clinical grounds and elevated serum IgD levels (>100 U/ml), but requires a high index of suspicion, and a mevalonate kinase enzyme defect. Most patients are from western Europe but there are others identified in other countries. We describe a 17-year-old patient who had been followed with the diagnosis of familial Mediterranean fever for a long time before she was diagnosed with hyper-IgD syndrome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15045637     DOI: 10.1007/s10067-003-0858-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  14 in total

Review 1.  Hereditary periodic fever.

Authors:  J P Drenth; J W van der Meer
Journal:  N Engl J Med       Date:  2001-12-13       Impact factor: 91.245

Review 2.  [Identification of the gene for hyper-IgD syndrome: a model of modern genetics].

Authors:  J P Drenth; H R Waterham; W Kuis; S M Houten; J Frenkel; R J Wanders; B T Poll-The; J W van der Meer
Journal:  Ned Tijdschr Geneeskd       Date:  2000-04-22

3.  [Periodic fever due to hyper-IgD syndrome].

Authors:  I M Wauters; R K Linskens; C D Stehouwer
Journal:  Ned Tijdschr Geneeskd       Date:  2000-04-22

4.  Molecular analysis of MVK mutations and enzymatic activity in hyper-IgD and periodic fever syndrome.

Authors:  L Cuisset; J P Drenth; A Simon; M F Vincent; S van der Velde Visser; J W van der Meer; G Grateau; M Delpech
Journal:  Eur J Hum Genet       Date:  2001-04       Impact factor: 4.246

5.  Familial Mediterranean Fever: association of elevated IgD plasma levels with specific MEFV mutations.

Authors:  M Medlej-Hashim; I Petit; S Adib; E Chouery; N Salem; V Delague; M Rawashdeh; I Mansour; G Lefranc; R Naman; J Loiselet; J C Lecron; J L Serre; A Mégarbané
Journal:  Eur J Hum Genet       Date:  2001-11       Impact factor: 4.246

6.  Molecular analysis of the mevalonate kinase gene in a cohort of patients with the hyper-igd and periodic fever syndrome: its application as a diagnostic tool.

Authors:  A Simon; L Cuisset; M F Vincent; S D van Der Velde-Visser; M Delpech; J W van Der Meer; J P Drenth
Journal:  Ann Intern Med       Date:  2001-09-04       Impact factor: 25.391

7.  Familial Mediterranean fever and hyperimmunoglobulinemia D syndrome: two diseases with distinct clinical, serologic, and genetic features.

Authors:  A Livneh; J P Drenth; I S Klasen; P Langevitz; J George; D A Shelton; D L Gumucio; E Pras; D L Kastner; M Pras; J W van der Meer
Journal:  J Rheumatol       Date:  1997-08       Impact factor: 4.666

Review 8.  Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health.

Authors:  J Samuels; I Aksentijevich; Y Torosyan; M Centola; Z Deng; R Sood; D L Kastner
Journal:  Medicine (Baltimore)       Date:  1998-07       Impact factor: 1.889

9.  Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome.

Authors:  J P Drenth; M van Deuren; J van der Ven-Jongekrijg; C G Schalkwijk; J W van der Meer
Journal:  Blood       Date:  1995-06-15       Impact factor: 22.113

10.  [Hyper-IgD syndrome (HIDS)].

Authors:  R Scolozzi
Journal:  Recenti Prog Med       Date:  1995-06
View more
  2 in total

1.  Different clinical presentation of the hyperimmunoglobulin D syndrome (HIDS) (four cases from Turkey).

Authors:  Dıdem Arslan Tas; Suzan Dınkcı; Eren Erken
Journal:  Clin Rheumatol       Date:  2012-01-14       Impact factor: 2.980

2.  Hyperimmunoglobulinemia D and periodic fever syndrome; treatment with etanercept and follow-up.

Authors:  Rezan Topaloğlu; Nuray Aktay Ayaz; Hans R Waterham; Aysel Yüce; Fatma Gumruk; Ozden Sanal
Journal:  Clin Rheumatol       Date:  2008-05-28       Impact factor: 2.980

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.